Company: PGEN
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001356090-25-000019
Chunk: 93

Company: PRECIGEN, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 8
Chunk 93
---
 $2.7 million of stock-based compensation expense, (iii) $0.6 million of depreciation and amortization expense, and (iv)  $0.5 million of shares issued as payment for services, partially offset by non-cash benefits of  $0.7 million due to amortization of discounts on investments. In addition, changes in operating assets and liabilities provided $2.2 million of cash for operating activities. 

During the three months ended March 31, 2024, our net loss was $23.7 million, which includes the following significant noncash expenses and benefits totaling $4.3 million: (i) $2.6 million of stock-based compensation expense, (ii) $1.6 million of depreciation and amortization expense and (iii) $0.5 million of shares issued as payment for services, offset by non-cash benefits of  $0.4 million due to amortization of discounts on investments.

Cash flows from investing activities:

During the three months ended March 31, 2025, we received $5.8 million of investments, from sales and maturities, net of purchases, and purchased $0.6 million of property, plant and equipment, primarily related to the build-out of our manufacturing facility.

During the three months ended March 31, 2024, we received $28.4 million of investments, from sales and maturities, net of purchases, and purchased $4.4 million of property, plant and equipment.

Cash flows from financing activities:

During the three months ended March 31, 2025, we paid $0.4 million in issuance costs related to a prior year equity issuance, paid $0.5 million to taxing authorities related to vesting of performance stock units, and received $0.2 million from the exercise of stock options. During the three months ended March 31, 2024, we did not have any cash inflows or outflows from financing activities.

Future capital requirements

Our future capital requirements will depend on many factors, including:

•progress in our research and development programs, as well as the magnitude and speed of development of these programs;

•capital expenditures to building out our manufacturing capabilities;

•the speed and scale of building our commercial operations as we prepare for commercial readiness:

•the timing of regulatory approval of our product candidates and those of our collaborations;

32

•the timing, receipt, and amount of any payments received in connection with strategic transactions;

•the timing, receipt